Release Date: November 30, 2022
Expiration Date: November 30, 2023
Activity Overview
Management of gastrointestinal (GI) cancers is rapidly evolving with a growing number of available treatment options. Appropriate treatment strategies should be carefully considered in the context of emerging clinical trial data to optimize patient outcomes.
This activity will update oncology health care professionals on the most recent data from key abstracts focusing on GI cancers that were presented at the 2022 European Society for Medical Oncology (ESMO) Congress, held in Paris, France, in September 2022. By placing the data in clinical context, oncology practitioners can assess and apply these findings to their clinical practice and ultimately improve care for their patients with GI malignancies.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, and other health care professionals who treat GI cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Detail the clinical study designs, patient characteristics, and end points of recently completed and ongoing investigations focused on novel approaches for the treatment of patients with gastrointestinal (GI) cancers
- Discuss efficacy and safety outcomes from recent studies that assessed novel strategies for the treatment of GI malignancies
- Place recent clinical trial results in the context of evolving paradigms in the field of GI malignancies’ management
John L. Marshall, MD
Professor of Medicine and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Chief, Division of Hematology/Oncology
MedStar Georgetown University Hospital
Director, The Ruesch Center for the Cure of Gastrointestinal Cancers
Washington, DC
Disclosures: Consultant: Bayer, Merck, Taiho, Pfizer, AstraZeneca, Caris. Speakers Bureau: Bayer, Merck, Taiho, Pfizer, AstraZeneca.
Geoffrey Y. Ku, MD
Medical Oncologist
Assistant Attending Physician
Section Head, Esophagogastric Section, Gastrointestinal Oncology Service
Member, Cellular Therapy Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Adaptimmune, Arog, AstraZeneca, BMS, CARsgen, Daiichi Sankyo, Merck, Oncolys BioPharma, Pieris, Zymeworks. Consultant: AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Merck, Pieris, Zymeworks.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here